Business
Visionary Holdings (NASDAQ: GV) Provides 2026–2027 Growth Outlook; RAMU Anti-Aging Product Line Targets Potential $30 Million Annual Sales
Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics StrategyHONG KONG, March 05, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”), a technology-driven multinational enterprise focused on healthcare services, medical aesthetics, and advanced biotechnology applications, today provided its 2026–2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healt
About this update from Visionary Holdings Inc.
[{"type":"text","content":"Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy","length":103,"tagName":"p"},{"type":"text","content":"HONG KONG, March 05, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”), a technology-driven multinational enterprise focused on healthcare services, medical aesthetics, and advanced biotechnology applications, today provided its 2026–2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healthcare and medical aesthetics markets.","length":434,"tagName":"p"},{"type":"text","content":"Over the past year, Visionary has progressively repositioned its strategic focus toward higher-margin healthcare services and medical aesthetics businesses. The Company has previously announced initiatives aimed at expanding into international healthcare markets, including North America and Europe, through product commercialization, healthcare service collaborations, and international distribution partnerships.","length":414,"tagName":"p"},{"type":"text","content":"Management believes that the global medical aesthetics and anti-aging industry continues to demonstrate strong long-term growth potential, driven by increasing consumer demand for advanced aesthetic treatments and regenerative healthcare solutions.","length":248,"tagName":"p"},{"type":"text","content":"2026–2027 Business Outlook","length":26,"tagName":"p"},{"type":"text","content":"Management believes that the period from 2026 through 2027 may represent an important stage in the Company’s commercialization and international expansion within the healthcare and medical aesthetics sectors.","length":208,"tagName":"p"},{"type":"text","content":"Visionary expects that the commercialization of its RAMU anti-aging product line, part of the Company’s medical aesthetics and regenerative healthcare portfolio, may become an important driver of revenue growth during this period.","length":230,"tagName":"p"},{"type":"text","content":"Based on current market expansion plans and distribution arrangements, management believes that RAMU-related product sales could potentially reach approximately US$30 million in annual sales, subject to market conditions, regulatory approvals, and operational execution.","length":270,"tagName":"p"},{"type":"text","...